A questionnaire survey of pharmacists regarding the clinical practice guidelines for the appropriate use of granulocyte-colony stimulating factors

Table 4 Suggestion for the use of G-CSFs in individual cases. Primary prevention dosage of G-CSFs

	Q16. TC for breast cancer^a	Q17. CDDP + S-1 for gastric cancer^b	Q18. FOLFOXIRI for colorectal cancer^c
	n = 145	n = 187	n = 183
I recommend of primary prophylactic administration of G-CSFs	43 (29.7)^d	1 (0.5)	23 (12.6)
After Grade 4 neutropenia developed, I recommend G-CSFs	48 (33.1)	63 (33.7)	70 (38.2)
After FN developed, I recommend G-CSFs	54 (37.2)	66 (35.3)	56 (30.6)
I do not recommend G-CSFs	0 (0.0)	57 (30.5)	34 (18.6)

TC Docetaxel and Cyclophosphamide, CDDP Cisplatin, S-1 Tegafur, gimeracil, and oteracil, FOLFOXIRI Irinotecan, oxaliplatin, and 5-fluorouracil, G-CSF Granulocyte-Colony Stimulating Factor, FN Febrile Neutropenia
^aA 67-year-old woman. You plan to treat with TC therapy (docetaxel 75 mg / m² and cyclophosphamide 600 mg / m², administered every 3 weeks) as postoperative chemotherapy for breast cancer. What kind of suggestion do you do as a pharmacist?
^bA 70-year-old man. As first-line chemotherapy for unresectable gastric cancer, you plan to treat with S-1 and cisplatin combination therapy. What kind of suggestion do you do as a pharmacist?
^cA 70-year-old woman. You plan to treat with irinotecan, oxaliplatin and 5-fluorouracil (FOLFOXIRI) therapy as first-line chemotherapy for unresectable colon cancer. What kind of suggestion do you do as a pharmacist?
^dNumber (percent)

ISSN: 2055-0294